Royalty pharma acquires additional royalty interests in BioCryst's BCX9930 and Orladeyo

Makhbubakhon Ismatova/iStock via Getty Images

• BioCryst Pharmaceuticals (NASDAQ:BCRX), Royalty Pharma (NASDAQ:RPRX), and OMERS Capital Markets announce transactions totaling $350M in new funding for BioCryst, with all funds immediately available at closing.
• BCRX shares rise 7.5% premarket at $12.78, RPRX up 2.2% at $42.46.
• The